KP 2647

1
KP 2647

• The unique dietary supplement supported by science

Kunpoong Bio Co., Ltd. Kunpoong_at_kunpoong.co.kr,
http//kpbio.com
2
Biological Efficacy of KP 2647

• 1. The unique dietary supplement for
• Anti-Lipocyte Differentiation
• supported by science

3
Scientific Literature on KP 2647TM
KP 2647TM prevent PPAR-gamma expression in
introduced Fat-liver by fed ethanol
Euk-Ok Kang, Young-Joon Jin, Ji-Gweon Park, Gi-Ok
Kim, Se-Jae Kim Department of Technology
Innocation Center, Cheju National University
KP 2647TM is a natural compound from based on
mid-molecular weight Chitosan, that extracted
from the shells of crutaceans. Chitosan is the
deacetylated form of chitin that is wild
distributed in microorganism, fungi, crutaceans
And plants. Whereas the polysaccharide used for
purpose of industrial medical, biomedical, and
diet, but mid-molecular weight Chitosan did
unknown. We studied the effect of polymeric
Chitosans (US and Norway origin) and KP 2647TM on
suppression of lipid droplet in ethanol-induced
Liver injury. Blood-glucose, total cholesterol
level and lipid droplet formation in liver were
significantly reduced in fed KP 2647TM group than
other group. The FAS (fatty acid synthease),
PPAR-a, PPAR-r and HMG-CoA reductase mRNA were
lower expressed in fed KP 2647TM mice liver. In
particular, expression of PPAR-r was corrected
with reduced droplet in liver. These result
suggest that KP 2647TM is prevent the formation
of liver-lipid-droplet in fed ethanol mice.
Proceeding of Current Biotechnology and
Bioengineering (XIII) October 22-24,
2003 COEX, Seoul, Korea, Proceeding P. 642 The
Korean Society for Biotechnology and
Bioengineering http//www.ksbb.or.kr, T.
02-556-2164
4
Carbohydrate, Fat, Alcohol
Glucose
Acetyl- CoA
Malonyl CoA
FAS
3-hydroy-3-methygutatyl CoA (HMG-CoA)
Fatty acid
statin
HMG-CoA reductase
mevalonate
TG
Isopententy phosphate
PPARs
Gernyl-p
Farnzyl-p
Choresterol
5
(No Transcript)
6
PPRE sequence
7
KP 2647 protect the differentiation of lipocyte.
FAS
PPAR-r
?-actin
M 1 2 3 4 5 6
7 8 9 10 11
1 normal (preadipocyte) 2 insun (adipocyte) 3
insulinchitosan A 10ug 4
50ug 5
100 ug 6 chitosan B 10 ug 7
50 ug 8
100 ug 9 insulinKP 2647 10 ug 10
50 ug 11
100 ug
8
(No Transcript)
9
Table. Comparison Data between normal Chitosan
and KP 2647 In terms of Liver and body weight
(Rat)
10
A
B
C
1 Normal Feed 2 7.5 EtOH 3 7.5
EtOHChitosan A 4 7.5 EtOHChitosan B 5 7.5
EtOHKP 2647
Fig. Comparison between normal Chitosan and KP
2647 in terms of HDL, Total Cholesterol and Blood
Glucose Level
11
NORMAL
7.5 EtoH
7.5 EtoH20mg Normal Chitosan A
12
7.5 EtoH20mg Normal Chitosan B
7.5 EtoH20mg KP 2647
Fig. Comparison between normal Chitosan and KP
2647 (Microscope of rat liver-tissue)
13
7.5 EtoH
Normal Feed
p
n
k
7.5 EtoH20mg KP 2647
7.5 EtoH20mg Chitosan
14
PPAR-?
HMG-CoA
FAS
PPAR-?
?-actin
EtOH
Control
KP 2647 20mg
Chitosan A 20mg
Chitosan B 20mg
15
Normal Feed 7.5 EtOH Chitosan
A Chitosan B KP 2647
PPAR-?
50 Kb
Poncer (loading control)
Fig. Gene Expression profile on PPAR between
normal Chitosan and KP 2647
16

• Abstract
• Chitosan polymer does not affect to the gene
  expression concerning the lipocyte related gene
  PPAR-r.
• KP 2647 reduce the level of total choresterol and
  blood glucose level.
• KP 2647 inhibit the formation fatty-liver
  significantly.
• KP 2647 significantly inhibit the PPAR-r gene
  (which directly related to lipocyte) expression.

Conclusion KP 2647 as a dietary supplement can
protect the fatty-liver formation Through PPAR-r
gene expression inhibition.
17
Future direction on KP 2647

• Cardiovascular desease mice
• Gene Expression study on Human Body Lipid
• PPAR-r target molecule

18
(No Transcript)
19
(No Transcript)
20
(No Transcript)
21
Biological Efficacy of KP 2647

• 2. The unique dietary supplement for
• Penile Erectile Dysfunction
• supported by science

22
Born of KP 2647

• KP 2647 was originally investigated as a
  potential immune booster. Although KP 2647
  failed as a potent immune boosting health food
  ingredient, researchers in Kunpoong Bio became
  excited when it shows significant ability to
  release nitric oxide, which produces cyclic
  guanosine monophosphate (c-GMP) to induce
  erection.
• According to this matter, many of the men in the
  clinical trials reported the frequent occurrence
  of unaccustomed erections and improved sexual
  performance.

23
Proposed Mechanism of Action (In terms of nitric
oxide release)

• The physiologic mechanism of erection of the
  penis involves release of nitric oxide (NO) in
  the corpus cavernosum during sexual stimulation.
  NO then activates the enzyme guanylate cyclase,
  which results in increased levels of cyclic
  guanosine monophosphate (cGMP), producing smooth
  muscle relaxation in the corpus cavernosum and
  allowing inflow of blood.
• KP 2647 has no direct relaxant effect on
  isolated human corpus cavernosum, but enhances
  the effect of nitric oxide (NO), which is
  responsible for degradation of cGMP in the corpus
  cavernosum. When sexual stimulation causes local
  release of NO by KP 2647 causes increased levels
  of cGMP in the corpus cavernosum, resulting in
  smooth muscle relaxation and inflow of blood to
  the corpus cavernosum. KP 2647 at recommended
  doses has no effect in the absence of sexual
  stimulation, which is same as sildenafil citrate
  (viagra).

24
NO Production Proposed Mechanism of KP 2647
KP 2647
NANC
NO
Endotherial cells
Guanylate cyclase
cGMP
GTP GMP
relax
Penile Erection
25
Clinical Trials with patients of erectile
dysfunction

• Patients 65 cases (avg. 45.16.4 years old)
• Dosage 300mg 450mg for total 2 weeks (1 week
  as serial)
• Data were pooled and analyzed using 5 categories
  for sexual functions among
• International Index of Erectile Function-5
  (IIEF-5).

Fig 1. Effect of KP 2647 on mean domain score of
IIEF-5. The clinical effect of KP 2647 was
significantly higher than that of pretreatment
mean domain score (plt0.01)
Fig 2. Clinical efficacies evaluated by
improvement of mean IIEF-5 score according to
each treatment with KP 2647.

Effect of KP 2647TM in Patients with Erectile
Dysfunction H. Chung 1) , S.L. Park 2) ,
S.C.Kim 2) , C. W. Sung 2) , J. W. Lee 2) Chung
Euro Derma Clinic, Seoul, Korea 1) Central
Research Institute of Kunpoong Bio, Korea 2)
26
Dosage, Safety and Side-Effect
Recommended Dosage The recommended dosage of KP
2647 is 600 milligrams per day. Maximum dose
level for most patients is 3,000 milligrams per
day, according to Kunpoong Bio.
Safety According to the Acute oral toxicity test,
The overall results indicate that LD50 of KP
2647 is above 2 g/kg B.W. in this
test. (TBH-000039, (Dr.) Park Hark Soo, Korea
Testing Research Institute for Chemical
Industry)
Side-Effect The most common side effects on
hypersensitive patients of KP 2647 include
pruritus, headaches, facial flushing,
hemophthalmia, and indigestion, if one was dosed
over 20,000 milligrams per day. If one desires
to be dosed over 10,000 milligrams per day, a
combination of KP 2647 and a vasodilating drug
like nitroglycerin might result in a drop in
blood pressure. This is due to the molecules
action of enhancing the smooth muscle relaxing
effects of nitric oxide.
.
27
Acute oral toxicity test Report (TBH-000039,
(Dr.) Park Hark Soo, Korea Testing Research
Institute for Chemical Industry)
28
Cytotoxicity test Report(TBH-000038, (Dr.) Park
Hark Soo, Korea Testing Research Institute for
Chemical Industry)
29
Certificate of Analysis
KP 2647 Water-Soluble Chitosan 22 Rest of Them
(as career) Bright Yellow Powder Pass 10
cps 10 0.5 5mg/kg 1 x 103/g 1 x 10/g 10kgs in
Carton Box
Commercial Name API (Active Principle
Ingredient) Assay (as tot. Glucosamine) Maltodextr
in Appearance Solubility (pH 3-10) Viscosity Moist
ure Ash Heavy Metal Total Plate Count Yeast and
Mould Packaging
30
Solubility and Stability of KP 2647 (in H2O
Ethyl alcohol)
31
Applications of KP 2647

• Health Food in Capsule or Tablet
• All kinds of Beverages (includes alcoholic
  beverage as well)
• Bars
• Cereals

32
Contact
Japan CBC Co., Ltd. Fine Chemicals Foods
Division Osaka Foods Feedstuff Group Ehime
Bldg., 1-7-7, Kawaramachi, Chuo-ku, Osaka T.
(81 6) 6206 5047 F. (81 6) 6222
0606 Tashiro_at_cbc.co.jp
Italy A.C.E.F. spa 29017 Fiorenzuola Darda
(Piacenza) via Umbria 8/14 T. 0523 24 19 11 F.
0523 24 19 37 Integratori_at_acef.it
Taiwan Progen International Co., Ltd. 7FL-3,No.
2. Sec. 2, HSIN Sheng South Rd. Taipei, Taiwan
ROC   (T.02 2351 5492)
Spain Portugal Nutraceuticos Portal del Rey, 3
Oficina 10 01001 Vitoria T. 945 125 002 F. 945
124 807 Baceiredo_at_nutraceuticos.net
Manufactured by Kunpoong Bio Co, Ltd. 903,
Wooree Venture, 684-2, Deungchon, Gangseo, Seoul,
Korea T. (82 2) 3662 8565, F. (82 2) 3662
8385 Kunpoong_at_kunpoong.co.kr Kpbio.com